Lunit Insight News Today

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region. Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, respectively.

Using artificial intelligence to analyse mammograms for signs of breast cancer, but with human oversight, can save many lives through early detection and diagnosis, says a radiologist testing the technology.

South-east Asian nations strike a balance between taking advantage of AI tools and preventing abuse of the platforms. Read more at straitstimes.com.

Lunit announced the results of its study demonstrating the effectiveness of artificial intelligence (AI) solutions in cancer diagnostics.

Hungary has become a major testing ground for A.I. software to spot breast cancer. Doctors debate whether the technology will replace them.

Hungary has become a major testing ground for A.I. software to spot cancer, as doctors debate whether the technology will replace them in medical jobs.

[Courtesy of Lunit]SEOUL -- "Lunit INSIGHT MMG," a solution specialized in detecting breast cancer created by South Koreas medical artificial intelligence company Lunit, was adopted by a medical diagnostic imaging center in Hong Kong and a state-run hospital in Mongolia. The adoption

New advancements have the potential to improve early breast cancer detection, but the industry must first overcome the barriers limiting patient access to screening

Protein Labeling Market Size Estimated to Reach $3.4 Billion by 2027

Protein Labeling Market Size Estimated to Reach $3.4 Billion by 2027